Bird & Bird has appointed Weishi Li as partner in the Shanghai office. Weishi will play an important role helping to build the firm’s transactional and IP expertise in the region, working closely with other partners in the firm’s mainland China and Hong Kong offices.
Weishi specialises in commercial technology, licensing and IP work, with a particular expertise in the technology, life sciences and healthcare sectors. Weishi has extensive experience assisting multinational companies and Chinese companies in structuring and negotiating cross-border technology-related transactions such as licensing, strategic alliances, joint ventures, distribution and OEM. She has also regularly provided IP counselling to leading PE/VC funds and multinational companies in investing into or acquiring technology and life sciences companies in China.
Commenting on Weishi’s appointment, Matthew Laight, Managing Partner of Bird & Bird China, comments: “We are delighted to welcome Weishi to the firm as her appointment underpins our strategy in China to complement our deep industry knowledge in sectors such as life sciences and IT, with strong transactional expertise. Given our leading reputation for understanding technology-rich industries, we are well placed and look forward to addressing the market demands in China for top quality legal advice in life sciences, IT and healthcare.